Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Total Liabilities
Everything the company owes to creditors and other parties.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 56.1% from a year ago
Total liabilities stood at $59.46M at the end of Q1 FY2026, up 56.1% from a year earlier and down 18.2% from the prior quarter. Over 3 fiscal years it compounded at +42.6% a year.
Context
- Total liabilities amounted to 49.7% of total assets at the end of Q1 FY2026, up 22.7 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +56.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 72.68M USD
- Year-over-year change
- +65.0%
- 4-year CAGR
- +39.5%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.68M | +65.0% |
| FY2024 | 2024-12-31 | 44.06M | +8.6% |
| FY2023 | 2023-12-31 | 40.58M | +61.9% |
| FY2022 | 2022-12-31 | 25.06M | +30.5% |
| FY2021 | 2021-12-31 | 19.2M | — |
Total Liabilities vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +56.1% is the 4th highest of 11, against a peer median of +17.7%.
- Total liabilities amounts to 49.7% of total assets for PRLD, versus a peer median of 40.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B USD | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M USD | -6.8% | -8.8% | 134.4% | |
| Dec 2025 | €277.91M EUR | +23.2% | +57.9% | 111.7% | |
| Mar 2026 | $198.12M USD | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $59.46M USD | +56.1% | +42.6% | 49.7% | |
| Mar 2026 | $49.69M USD | +17.8% | +6.2% | 49.4% | |
| Mar 2026 | $46.98M USD | -16.8% | -10.0% | 31.5% | |
| Mar 2026 | $33.03M USD | +0.8% | -9.0% | 51.4% | |
| Mar 2026 | $31.57M USD | +98.4% | -9.0% | 31.6% | |
| Mar 2026 | $28.88M USD | +17.6% | -12.7% | 21.4% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $9.2M USD | +318.0% | -29.3% | 6.3% |
| Peer median (excluding PRLD) | — | +17.7% | -8.9% | 40.5% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 31.83M | 30.61M | 25.29M | 12.47M | 35.26M |
| Short-term Investments | 259.41M | 171.12M | 207.64M | 121.14M | 67.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.65M | 2.65M | 2.28M | 2.48M |
| Total Current Assets | 295.12M | 204.38M | 235.59M | 135.9M | 105.69M |
| Property, Plant & Equipment (Net) | 5.64M | 6.7M | 37.74M | 35.47M | 32.28M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.35M | 9.42M | 4.34M | 4.15M | 3.35M |
| Total Non-current Assets | 9.98M | 16.12M | 42.08M | 39.62M | 35.62M |
| Total Assets | 305.1M | 220.5M | 277.67M | 175.52M | 141.32M |
| Account Payables | 7.84M | 6.78M | 4.58M | 7.73M | 3.98M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 33.73M |
| Other Current Liabilities | 5.01M | 6.21M | 6.61M | 9.79M | 5.4M |
| Total Current Liabilities | 19.2M | 21.7M | 21.83M | 25.64M | 52.99M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.8M |
| Other Non-current Liabilities | 0 | 3.36M | 3.34M | 3.09M | 2.84M |
| Total Non-current Liabilities | 0 | 3.36M | 18.75M | 18.42M | 19.68M |
| Total Liabilities | 19.2M | 25.06M | 40.58M | 44.06M | 72.68M |
| Common Stock | 5K | 5K | 5K | 5K | 5K |
| Retained Earnings | (219.12M) | (334.56M) | (456.39M) | (583.56M) | (683.06M) |
| Accumulated OCI | (711K) | (1.69M) | 223K | 35K | 8K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 285.9M | 195.44M | 237.09M | 131.46M | 68.64M |
| Total Debt | 1.74M | 1.83M | 16.89M | 18.03M | 17.79M |
| Net Debt | (30.09M) | (28.77M) | (8.4M) | 5.55M | (17.47M) |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.